Advertisement

Der Internist pp 745-754 | Cite as

Was ist gesichert in der Behandlung der Campylobacter-pylori-induzierten Gastritis und des Campylobacter-pylori-assoziierten peptischen Ulkus?

  • H. Menge
Chapter

Zusammenfassung

Die mikrobiologische Isolierung von Campylobacter pylori gelang 1983. Scither werden zunehmend Erkenntnisse gewonnen, die darauf hinweisen, daß die chronische Typ-B-Gastritis überwiegend durch diesen Keim hervorgerufen wird (wohl im Gefolge einer akuten Campylobacter-pylori-Gastritis) und das peptische Geschwür aus einer synergistisch schädigenden Wirkung von Magensäure und Campylobacter pylori resultiert. Ausgehend von diesen Vorstellungen wurden und werden neue Behandlungsmethoden für die chronische Typ-B-Gastritis und das Ulkusleiden erprobt, deren gemeinsames Ziel eine dauerhafte Eradikation des Keimes ist. Die bisherigen Ergebnisse dieser Studien sollen an dieser Stelle kritisch gewürdigt werden. Da Wismutsalze das Basistherapeutikum fast aller Bemühungen zur Elimination des Erregers darstellen, sollen ihre Wirkungen und Nebenwirkungen jedoch zunächst dargestellt werden.

Schlüsselwörter

Campylobacter pylori Ulcus duodeni Ulcus ventriculi Wismut-Subsalizylat Wismut-Subzitrat H2-Rezeptorantagonisten 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Bader JP (1987) The safety profile of DeNol®. Digestion 37 [Suppl 2] : 53–59PubMedCrossRefGoogle Scholar
  2. 2.
    Baron JH, Barr J, Batten J, Sidebotham R, Spencer J (1986) Acid, pepsin, and mucus secretion in patients with gastric and duodenal ulcer before and after colloidal bismuth subcitrate (De-Nol). Gut 27:486–490PubMedCrossRefGoogle Scholar
  3. 3.
    Bayerdörffer E, Kasper G, Pirlet Th, Sommer A, Ottenjann R (1987) Ofloxacin in der Therapie Campylobacter-pylori-positiver Ulcera duodeni. Eine prospektive kontrollierte randomisierte Studie. Dtsch Med Wochenschr 112:1407–1411PubMedCrossRefGoogle Scholar
  4. 4.
    Bianchi Porro G, Lazzaroni M, Petrillo M, De Nicola C (1984) Relapse rates in duodenal ulcer patients formerly treated with bismuth subcitrate or maintained with Cimetidine. Lancet II: 698CrossRefGoogle Scholar
  5. 5.
    Bianchi Porro G, Parente F, Lazzaroni M (1987) Tripotassium dicitrato bismuthate (TDB) versus two different dosages of Cimetidine in the treatment of resistant duodenal ulcers. Gut 28:907–911PubMedCrossRefGoogle Scholar
  6. 6.
    Börsch G, Schmidt G, Wegener M, Sandmann M, Adamek R, Leverkus F, Reitemeyer E (1988) Campylobacter pylori: prospective analysis of clinical and histological factors associated with colonization of the upper gastrointestinal tract. Eur J Clin Invest 18:133–138PubMedCrossRefGoogle Scholar
  7. 7.
    Borody T, Daskalopoulos G, Brandi S, Carrick J, Hazell S (1987) Dyspeptic symptoms improve following eradication of gastric Campylobacter pyloridis. Gastroenterology 92:1324Google Scholar
  8. 8.
    Borody T, Hennessy W, Daskalopoulos G, Carrick J, Hazell S (1987) Double blind trial of De-Nol in non-ulcer dyspepsia associated with Campylobacter pyloridis gastritis. Gastroenterology 92:1324Google Scholar
  9. 9.
    Borody T, Cole P, Noonan S, Morgan A, Ossip G, Maysey J, Brandi S (1988) Long-term Campylobacter pylori recurrence post-eradication. Gastroenterology 94: A43Google Scholar
  10. 10.
    Burnie J, Lee W, McNulty C, Dent J (1988) Virulence of Campylobacter strains and degree of gastritis. Lancet II:302CrossRefGoogle Scholar
  11. 11.
    Coghlan JG, Humphries H, Dooley C, Keane C, Gilligan D, McKenna D, Sweeney E, O’Morain C (1987) Campylobacter pylori and recurrence of duodenal ulcers — a 12-month follow-up study. Lancet II:1109–1111CrossRefGoogle Scholar
  12. 12.
    Domarus v A, Heubner W, Krautwald A (1945) Arzneiverordnungen — Ratschläge für Studenten und Ärzte. Hirzel, Leipzig, S 61–63Google Scholar
  13. 13.
    DuPont HL (1987) Bismuth subsalicylate in the treatment and prevention of diarrheal disease. Drug Intell Clin Pharm 21:687–693PubMedGoogle Scholar
  14. 14.
    Eberhardt R, Kasper G, Dettmer AS, Höchter W, Hagena D (1988) Wirkung von Wismutsubsalicylat versus Cimetidin auf Campylobacter pylori, Ulkusheilung und -rezidivrate. Med Klin 83:402–405Google Scholar
  15. 15.
    Elta G, Kern S, Nostrant T, Appelmann H (1987) Campylobacter like organisms in erosive gastroduodenitis. Gastroenterology 92:1382Google Scholar
  16. 16.
    Gilman R, Leon-Barua R, Ramirez-Ramos A, Morgan D, Recavarron S, Spira W, Watanabe P, Kraft W, Pearson A (1987) Efficacy of nitrofurans in the treatment of antral gastritis associated with Campylobacter pyloridis. Gastroenterology 92:1405Google Scholar
  17. 17.
    Glubczynski Y, Burette A, Labbe M, Deprez C, De Reuck M, Deltenre M (1988) Campylobacter pylori-associated gastritis: a double-blind placebo-controlled trial with Amoxycillin. Am J Gastroenterol 83:365–372Google Scholar
  18. 18.
    Goodwin CS, Marshall BJ, Blincow ED, Wilson DH, Blackbourn S, Phillips M (1988) Prevention of nitroimidazole resistance in Campylobacter pylori by coadministration of colloidal bismuth subcitrate : clinical and in vitro studies. J Clin Pathol 41:207–210PubMedCrossRefGoogle Scholar
  19. 19.
    Goodwin CS, Armstrong JA, Wilson DH (1988) Differences between in vitro and in vivo sensitivity of Campylobacter pylori to antibacterials. In: Menge H, Gregor M, Tytgat GNJ, Marshall BJ (eds) Campylobacter pylori. Springer, Berlin Heidelberg New York, pp 29–36CrossRefGoogle Scholar
  20. 20.
    Gruselle P (1976) Traitement oral par les sels insolubles de bismuth et syndrome d’encéphalopathie avec myoclonies. Louvain Méd 95:541–546Google Scholar
  21. 21.
    Holroyde MJ, Yeakle C, Pepple S (1984) Gastric cytoprotection by bismuth subsalicylate. Gastroenterology 86:1116Google Scholar
  22. 22.
    Hui WM, Lam SK, Ho J, Ng MMT, Lui I, Lai CL, Lok ASF, Lau WY, Poon GP, Choi S, Choi TK (1986) Chronic antral gastritis in duodenal ulcer. Natural history and treatment with prostaglandin E 1. Gastroenterology 91:1095–1101Google Scholar
  23. 23.
    Komoda T, Sonoda M, Ikeda M, Hokari S, Sakagishi Y (1981) Inhibition of alkaline phosphatase by bismuth. Clin Chim Acta 116:161–169PubMedCrossRefGoogle Scholar
  24. 24.
    Konturek SJ, Bilski J, Kwiecien N, Obtulowicz W, Kopp B, Oleksy J (1987) De-Nol stimulates gastric and duodenal secretion through prostaglandin dependent mechanisms. Gut 28:1557–1563PubMedCrossRefGoogle Scholar
  25. 25.
    Konturek SJ, Radecki T, Piastucki I, Brzozowski T, Drozdowicz D (1987) Gastrocytoprotection by colloidal bismuth subcitrate (De-Nol) and sucralfate. Role of endogenous prostaglandins. Gut 28:201–205PubMedCrossRefGoogle Scholar
  26. 26.
    Konturek SJ, Stachura J, Radecki T, Drozdowicz D, Brzozowski T (1987) Cytoprotective and ulcer healing properties of prostaglandin E2, colloidal bismuth and sucralfate in rats. Digestion 38:103–113PubMedCrossRefGoogle Scholar
  27. 27.
    Konturek SJ, Brzozowski T, Drozdowicz D, Bielanski W (1988) Gastropro-tective and ulcer healing properties of bismuth salts. In: Menge H, Gregor M, Tytgat GNJ, Marshall BJ (eds) Campylobacter pylori. Springer, Berlin Heidelberg New York, pp 184–192CrossRefGoogle Scholar
  28. 28.
    Konturek SJ, Dembinski A, Warzecha Z, Bielanski W, Brzozowski T, Drozdowicz D (1988) Epidermal growth factor (EGF) in the gastroprotective and ulcer healing actions of colloidal bismuth subcitrate (De-Nol) in rats. Gut 29:894–902PubMedCrossRefGoogle Scholar
  29. 29.
    Konturek SJ (1988) Role of epidermal growth factor in gastroprotection and ulcer healing. Scand J Gastroenterol 23:129–133PubMedCrossRefGoogle Scholar
  30. 30.
    Koo J, Ho J, Lam SK, Wong J, Ong GB (1982) Selective coating of gastric ulcer by tripotassium dicitrato bismuthate in the rat. Gastroenterology 82:864–870PubMedGoogle Scholar
  31. 31.
    Lagier G (1980) Encéphalopathies bismuthiques: situation dans les pays autres que la France. Thérapie 35:315–317PubMedGoogle Scholar
  32. 32.
    Lam SK, Lee NW, Koo J, Hui WM, Fok KH, Ng M (1984) Randomised crossover trial of tripotassium dicitrato bismuthate versus high dose Cimetidine for duodenal ulcers resistant to standard dose of Cimetidine. Gut 25:703–706PubMedCrossRefGoogle Scholar
  33. 33.
    Lambert JR, Borromeo M, Korman MG, Hansky J (1987) Role of Campylobacter pyloridis in non-ulcer dyspepsia — a randomized controlled trial. Gastroenterology 92:1488Google Scholar
  34. 34.
    Lanza FL, Rack MF, Peterson DF (1986) Eradication of Campylobacter pyloridis with bismuth subsalicylate. Am J Gastroenterol 81:853Google Scholar
  35. 35.
    Lechat P, Kisch R (1986) Les encéphalopathies bismuthiques : réévaluation du risque. Gastroenterol Clin Biol 10:562–569PubMedGoogle Scholar
  36. 36.
    Malfertheiner P, Stanescu A, Baczako K, Vanek E, Bode G, Ditschuneit H (1988) Wismutsubsalicylat-Behandlung bei Campylobacter-pylori-assoziierter chronischer erosiver Gastritis. Dtsch Med Wochenschr 113:923–929PubMedCrossRefGoogle Scholar
  37. 37.
    Marshall BJ, Armstrong JA, McGechie DB, Glancy RJ (1985) Attempt to fulfil Koch’s postulates for pyloric Campylobacter. Med J Aust 142:436–439PubMedGoogle Scholar
  38. 38.
    Martin DF, May SJ, Tweendle DEF, Hollanders D, Ravenscroft MM, Miller JP (1981) Difference in relapse rates of duodenal ulcer after healing with Cimetidine or tripotassium dicitrato bismuthate. Lancet I:7–10CrossRefGoogle Scholar
  39. 39.
    McNulty CAM, Gearty JC, Crump B, Davis M, Donovan IA, Melikian V, Lister DM, Wise R (1986) Campylobacter pyloridis and associated gastritis: investigator blind, placebo controlled trial of bismuth salicylate and erythromycin ethylsuccinate. Br Med J 293:645–649CrossRefGoogle Scholar
  40. 40.
    Menge H, Hofman J, Boenigk U, Gregor M (1988) Attempts to eradicate Campylobacter pylori — German experiences. In: Menge H, Gregor M, Tytgat GNJ, Marshall BJ (eds) Campylobacter pylori. Springer, Berlin Heidelberg New York, pp 228–230CrossRefGoogle Scholar
  41. 41.
    Menge H (1988) Chronische Gastritiden können bakteriell bedingt sein. Eine kritische Bewertung der bisherigen Studienergebnisse. Dtsch Ärztebl 85:2433–2437Google Scholar
  42. 42.
    Rauws EAJ, Langenberg W, Houthoff HJ, Zanen HC, Tytgat GNJ (1988) Campylobacter pyloridis-associated chronic active antral gastritis. A prospektive study of its prevalence and the effects of antibacterial and antiulcer treatment. Gastroenterology 94:33–40PubMedGoogle Scholar
  43. 43.
    Rösch W (1987) Therapie des peptischen Ulkus und der chronischen Gastritis mit Wismutsalzen. Z Gastroenterol 25 [Suppl 4]:34–40PubMedGoogle Scholar
  44. 44.
    Serfontein WJ, Mekel R (1979) Bismuth toxicity in man — II. Res Commun Chem Pathol Pharmacol 26:391–411PubMedGoogle Scholar
  45. 45.
    Smith AC, Price AB, Borriello P, Levi AJ (1988) A comparison of ranitidine and tripotassium dicitrato-bismuth (T.D.B.) in relapse rates of duodenal ulcer. The role of Campylobacter pylori (C.p.). Gastroenterology 94: A431Google Scholar
  46. 46.
    Soldani G, Del Tacca M, Bernardini C, Polloni A, Martinotti E, Malandrino S, Borsa M, Tonon GC (1985) Gastric pharmacological activities of tripotassium dicitrato bismuthate in rats and dogs. Pharmacol Res Commun 17:1017–1026PubMedCrossRefGoogle Scholar
  47. 47.
    Soutar RL, Coghill SB (1986) Interaction of tripotassium dicitrato bismuthate with macrophages in the rat and in vitro. Gastroenterology 91:84–93PubMedGoogle Scholar
  48. 48.
    Thomas DW, Hartley TF, Coyle P (1984) Bismut. In: Merian E (Hrsg) Metalle in der Umwelt. Verlag Chemie, Weinheim, S 343–349Google Scholar
  49. 49.
    Toukan AU, Kamal MF, Amr SS, Arnaout MA, Abu-Romiyeh AS (1985) Gastroduodenal inflammation in patients with nonulcer dyspepsia — A controlled endoscopic and morphometric study. Dig Dis Sci 30:313–320PubMedCrossRefGoogle Scholar
  50. 50.
    Tytgat GNJ (1986) Colloidal bismuth subcitrate in peptic ulcer disease. S Afr Med J 70:32–34Google Scholar
  51. 51.
    Tytgat GNJ, Nio CY (1987) Mucosa protectives : Sucralfate and colloidal bismuth subcitrate in peptic ulcer disease. Z Gastroenterol 25 [Suppl 3] : 152–161PubMedGoogle Scholar
  52. 52.
    Winship KA (1983) Toxicity of bismuth salts. Adv Drug React Ac Pois Rev 2:103–121Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1988

Authors and Affiliations

  • H. Menge
    • 1
  1. 1.Medizinische Klinik II (Abteilung für Innere Medizin mit Schwerpunkt Gastroenterologie, Stoffwechsel-und Infektionskrankheiten), Krankenanstalten der Stadt Remscheid Akademisches LehrkrankenhausUniversität BonnRemscheid 11Deutschland

Personalised recommendations